The overall aim of Project 1 is to develop data, through the use of rat, mouse and human epithelial and endothelial cells isolated from the pulmonary, cardiovascular, and reproductive system, for use in Project 3 to construct and validate a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model to extrapolate human health risks associated with exposure to nanomaterials. Human exposure to nanomaterials may occur through occupational exposure, environmental exposure, or intentional use as a delivery vehicle for therapeutic agents. To date, the majority of animal studies on the toxicity associated with nanomaterials have focused on male or non-pregnant rodents. As discussed in the overall theme of this proposal, we are utilizing the pregnant rodent to model potentially susceptible populations at greater risk for adverse health effects associated with nanomaterial exposure.
In Specific Aim 1 of Project 1, we will generate, characterize, and radiolabel the two carbon-based nanomaterials in the graphene class, the fullerene C60 and forms of multiwalled carbon nanotube (MWCNT), that will be used in each project. Specifically, Project 1 will utilize unlabeled C60 and three forms of MWCNTs: end-capped MWCNTs, oxidation-damaged MWCNTs (MWCNT(COOH)n), and iron-containing oxidation-damaged MWCNTs (FemMWCNT(COOH)n). We will use the terms """"""""forms of MWCNTs"""""""" to refer to these three forms of MWCNTs. Project 1 will also utilize the carbon-14 uniformly labeled analogs [14C(U)]C60, [14C(U)]MWCNTs, [14C(U)]MWCNT(COOH)n, and [14C(U)]FemMWCNT(COOH)n. To begin providing data on the cellular fate of these nanomaterials for use in establishing a PBPK/PD model in Project 3, we will utilize three cell types to represent potential target organs: lung (alveolar type 1 &11 epithelial cells), the cardiovascular system (aortic endothelial cells), and the reproductive system (placental endothelial cells). In the first 2 years of Project 1, the distribution and effect of the nanoparticles will be evaluated in vitro using rat cells to complement the in vivo data obtained from Project 2. During Years 3-4, we will begin to validate the rat model by testing the in vitro effects of C60 and forms of MWCNTs on the same population of cells isolated from mice. Lastly, in Year 5 of Project 1, we will examine the effects of C60 and forms of MWCNTs on human epithelial and endothelial cells to extrapolate to human risk assessment. Project 1 co-Leaders will work closely with the Center Management Team and the National Institute of Environmental Health Sciences (NIEHS) Project Officer to determine any necessary changes in direction as data is developed. Project 1 co-Leaders will provide the in vitro results to Projects 2 and 3 co-Leaders as they become available to permit refinement of the scope of research in Projects 2 and 3. The effects of C60 and forms of MWCNTs at the cellular and sub-cellular level will be tested with the three Specific Aims outlined below.

National Institute of Health (NIH)
National Institute of Environmental Health Sciences (NIEHS)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZES1-SET-V)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Research Triangle Institute
Research Triangle
United States
Zip Code
Fennell, Timothy R; Mortensen, Ninell P; Black, Sherry R et al. (2017) Disposition of intravenously or orally administered silver nanoparticles in pregnant rats and the effect on the biochemical profile in urine. J Appl Toxicol 37:530-544
Holland, Nathan A; Thompson, Leslie C; Vidanapathirana, Achini K et al. (2016) Impact of pulmonary exposure to gold core silver nanoparticles of different size and capping agents on cardiovascular injury. Part Fibre Toxicol 13:48
Thompson, Leslie C; Holland, Nathan A; Snyder, Ryan J et al. (2016) Pulmonary instillation of MWCNT increases lung permeability, decreases gp130 expression in the lungs, and initiates cardiovascular IL-6 transsignaling. Am J Physiol Lung Cell Mol Physiol 310:L142-54
Anderson, Donald S; Patchin, Esther S; Silva, Rona M et al. (2015) Influence of particle size on persistence and clearance of aerosolized silver nanoparticles in the rat lung. Toxicol Sci 144:366-81
Shannahan, Jonathan H; Bai, Wei; Brown, Jared M (2015) Implications of scavenger receptors in the safe development of nanotherapeutics. Receptors Clin Investig 2:e811
Shannahan, Jonathan H; Podila, Ramakrishna; Brown, Jared M (2015) A hyperspectral and toxicological analysis of protein corona impact on silver nanoparticle properties, intracellular modifications, and macrophage activation. Int J Nanomedicine 10:6509-21
Snyder, Rodney W; Fennell, Timothy R; Wingard, Christopher J et al. (2015) Distribution and biomarker of carbon-14 labeled fullerene C60 ([(14) C(U)]C60 ) in pregnant and lactating rats and their offspring after maternal intravenous exposure. J Appl Toxicol 35:1438-51
Aldossari, Abdullah A; Shannahan, Jonathan H; Podila, Ramakrishna et al. (2015) Influence of physicochemical properties of silver nanoparticles on mast cell activation and degranulation. Toxicol In Vitro 29:195-203
Poitras, Eric P; Levine, Michael A; Harrington, James M et al. (2015) Development of an analytical method for assessment of silver nanoparticle content in biological matrices by inductively coupled plasma mass spectrometry. Biol Trace Elem Res 163:184-92
Shannahan, Jonathan H; Podila, Ramakrishna; Aldossari, Abdullah A et al. (2015) Formation of a protein corona on silver nanoparticles mediates cellular toxicity via scavenger receptors. Toxicol Sci 143:136-46

Showing the most recent 10 out of 24 publications